Table 1

Baseline characteristics of included studies

Author, year	Country	Study type	Population	Sample size	Age (years)	% male	Follow-up (months)	Confirmatory test	Year of testing	% positive HEV-IgG	% positive HEV-RNA	Serology assay used
Abravanel et al, 201225	France	Retrospective	Allo-HSCT and auto-HSCT candidates	88	51	65.9	6 months after transplant	Positive IgG/IgM/RNA	2009–2010	36.4	0	Adaltis/Wantai
Ankcorn et al, 201847	UK	Prospective	Allo-HSCT candidates	144	N/A	N/A	4–18	HEV-RNA/Ag	2016	N/A	2.08	N/A
Furfaro et al 202024	Italy	Retrospective	Allo-HSCT and auto-HSCT candidates	563	48	56.5	N/A	Positive IgG/RNA	2010–2015, 2017–2019	6.04	3.4	Wantai/Ultra
Koenecke et al, 201226	Germany	Retrospective	Allo-HSCT with elevated ALT	52	41	62	N/A	Positive IgG/RNA	1998–2004	5.8	0	Abbott
Reekie et al, 201848	UK	Cross-sectional	Allo-HSCT and auto-HSCT	259	N/A	N/A	N/A	HEV-RNA	2013–2015	N/A	0.39	N/A
Swartling et al, 202049	Sweden	Retrospective	Allo-HSCT candidates	236	N/A	N/A	25	Positive IgG/IgM/RNA	2008–2015	4.7	3.4	Diapro
Tang et al, 201950	China	Retrospective	Haploidentical allo-HSCT with elevated ALT	177	26	63.3	36.9	Positive IgG/IgM/RNA	2014–2017	N/A	3.9	MP Diagnostics
Versluis et al, 201320	The Netherlands	Retrospective	Allo-HSCT candidates	328	50.4	54	40.9	Positive IgG/IgM/RNA	2006–2011	12.9	2.4	Wantai
Willemse et al, 201751	The Netherlands	Retrospective	Allo-HSCT with elevated ALT	130	N/A	53.8	N/A	HEV-RNA	2005–2015	N/A	4	N/A

Ag, antigen; Allo-HSCT, allogeneic hematopoietic stem cell transplant; ALT, alanine transaminase; HEV, hepatitis E virus; N/A, not available.